34. Consolidated companies as of December 31, 2025 | | | | | | | | | | | | | | | Year ended December 31, | | | | | 2025 | | 2024 | | 2023 | Name of the subsidiary | | Country | | % voting right
Galapagos NV
(directly or
indirectly
through
subsidiaries) | | Change in %
voting right
previous
period (2025
vs 2024) | | % voting right
Galapagos NV
(directly or
indirectly
through
subsidiaries) | | % voting right
Galapagos NV
(directly or
indirectly
through
subsidiaries) | | | | | | | | | | | | CONTINUING OPERATIONS | | | | | | | | | | | GLPG US Inc. (formerly AboundBio Inc.) | | United States | | 100% | | | | 100% | | 100% | Galapagos B.V. (merged with CellPoint B.V.) | | The Netherlands | | 100% | | | | 100% | | 100% | Galapagos GmbH | | Switzerland | | 100% | | | | 100% | | 100% | GLPG US Holding Inc. (formerly Galapagos, Inc.) | | United States | | 100% | | | | 100% | | 100% | Galapagos NV | | Belgium | | Parent company | | | | Parent company | | Parent company | Galapagos Real Estate Belgium BV | | Belgium | | 0% | | -100% | | 100% | | 100% | Galapagos Real Estate Netherlands B.V. | | The Netherlands | | 100% | | | | 100% | | 100% | Galapagos U.K. Limited | | United Kingdom | | 100% | | | | 100% | | 0% | Galapagos SASU | | France | | 100% | | | | 100% | | 100% | Xenometrix, Inc. in liquidation | | United States | | 100% | | | | 100% | | 100% | Galapagos Holding PTE. LTD. | | Singapore | | 100% | | | | 100% | | 0% | Lakefront Biotherapeutics, Inc. | | United States | | 100% | | 100% | | 0% | | 0% | Galapagos Cell Therapeutics NV | | Belgium | | 100% | | 100% | | 0% | | 0% | Galapagos (Shanghai) Bioscience Co., Ltd. | | People's Republic of China | | 100% | | 100% | | 0% | | 0% | | | | | | | | | | | | DISCONTINUED OPERATIONS | | | | | | | | | | | Galapagos Biopharma Belgium BV | | Belgium | | 0% | | | | 0% | | 100% | Galapagos Biopharma Netherlands B.V. | | The Netherlands | | 0% | | | | 0% | | 100% | Galapagos Biopharma Spain S.L.U. | | Spain | | 0% | | | | 0% | | 100% | Galapagos Biopharma Italy S.r.l. | | Italy | | 0% | | | | 0% | | 100% | Galapagos Biopharma Germany GmbH | | Germany | | 0% | | | | 0% | | 100% | Galapagos Biopharma Sweden AB | | Sweden | | 0% | | | | 0% | | 100% | Galapagos Biopharma Norway AS | | Norway | | 0% | | | | 0% | | 100% | Galapagos Biopharma Finland Oy | | Finland | | 0% | | | | 0% | | 100% | Galapagos Biopharma Denmark ApS | | Denmark | | 0% | | | | 0% | | 100% | Galapagos Biopharma Austria GmbH | | Austria | | 0% | | | | 0% | | 100% | Galapagos Biopharma Ireland Ltd | | Ireland | | 0% | | | | 0% | | 100% | Galapagos Biotech Ltd (formerly Inpharmatica Ltd.) | | United Kingdom | | 0% | | | | 0% | | 100% |
There are no significant restrictions on the group’s ability to access or use assets, or settle liabilities, of one of the group’s subsidiaries. In December 2024, we signed a share purchase agreement regarding the shares of Galapagos Real Estate Belgium BV. The transaction was closed on March 31, 2025. On January 7, 2025, we incorporated Galapagos (Shanghai) Bioscience Co., Ltd., in the People’s Republic of China, and on February 14, 2025 we incorporated Galapagos Cell Therapeutics NV (formerly XYZ Spinco NV) in Belgium. On August 5, 2025, we incorporated Lakefront Biotherapeutics, Inc. in the United States.
|